Austedo Austedo XR: Uses, Side Effects, Dosage Guide Austedo and Austedo XR (deutetrabenazine) are used to treat involuntary movement disorders in tardive dyskinesia (TD) and Huntington's disease (Huntington's chorea) to help reduce the severity of symptoms and improve quality of life
Huntingtons Disease (HD) Chorea Treatment - AUSTEDO XR® The most common side effects of AUSTEDO XR are expected to be similar to AUSTEDO in people with Huntington’s disease or tardive dyskinesia These are not all the possible side effects of AUSTEDO XR or AUSTEDO Call your doctor for medical advice about side effects You are encouraged to report side effects of prescription drugs to the FDA
AUSTEDO XR AUSTEDO DOSAGE FORMS AND STRENGTHS • AUSTEDO XR and AUSTEDO are contraindicated in patients who are suicidal, and in patients with untreated or inadequately treated depression (4, 5 1) INDICATIONS AND USAGE AUSTEDO XR and AUSTEDO are vesicular monoamine transporter 2 (VMAT2) inhibitors indicated in adults for the treatment of: • Chorea associated with Huntington’s
Austedo: Huntingtons Disease Uses, Side Effects, Dosage Austedo is a prescription medication that is used to treat the involuntary movements (chorea) of Huntington's disease The most common side effects of Austedo in people with tardive dyskinesia include inflammation of the nose and throat (nasopharyngitis) and problems sleeping (insomnia) Austedo can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients
Approved Treatments for Huntingtons Disease Austedo and Austedo XR Available in tablets, the medications are taken orally once or twice daily, depending on the formulation Their active ingredient is similar to that of Xenazine, an older approved treatment for Huntington’s chorea, but it is designed to last longer in the body
AUSTEDO® XR: Tardive Dyskinesia and Huntingtons Chorea Treatment AUSTEDO® XR (deutetrabenazine) extended-release tablets is the first medication approved to treat both tardive dyskinesia and Huntington's disease chorea See safety info including Boxed Warning Teva Shared Solutions® 1-800-887-8100
Clinical Policy: Deutetrabenazine (Austedo, Austedo XR) Deutetrabenazine (Austedo ®, Austedo ® XR) is a vesicular monoamine transporter 2 (VMAT2) inhibitor FDA Approved Indication(s) Austedo and Austedo XR are indicated for the treatment of: • Chorea associated with Huntington’s disease • Tardive dyskinesia (TD) in adults Policy Criteria
Teva Announces FDA Approval of AUSTEDO® XR (deutetrabenazine . . . AUSTEDO XR AUSTEDO is the first and only vesicular monoamine transporter 2 (VMAT2) inhibitor approved by the U S Food and Drug Administration in adults for the treatment of tardive dyskinesia (TD) and for the treatment of chorea associated with Huntington’s disease (HD) AUSTEDO XR is the once-daily formulation of AUSTEDO
Austedo XR Approved: A New Treatment Option for Tardive . . . The US Food and Drug Administration (FDA) has approved Teva Pharmaceuticals’ Austedo XR (deutetrabenazine) as a once-daily pill treatment option, available in 4 new tablet strengths (30, 36, 42, 48 mg), indicated in adults for tardive dyskinesia (TD) and Huntington disease (HD) chorea control 1
Austedo (deutetrabenazine) for Huntington’s disease . . . There was also a dose-proportional exposure to Austedo XR in the blood for all pharmacokinetics parameters and over the recommended dose range (6-48 mg) Common side effects of Austedo The most common side effects associated with Austedo and Austedo XR in Huntington’s include: somnolence or sleepiness; diarrhea; dry mouth; fatigue
Huntington’s Disease (HD) Chorea | AUSTEDO XR . . . Voiceover Onscreen text: INDICATIONS AND USAGE AUSTEDO® XR (deutetrabenazine) extended-release tablets and AUSTEDO® (deutetrabenazine) tablets are indicated in adults for the treatment of chorea associated with Huntington’s disease and for the treatment of tardive dyskinesia
Deutetrabenazine: Uses, Dosage, Side Effects . . . - Drugs. com Deutetrabenazine FDA approval for treatment of chorea associated with Huntington’s disease was granted on April 3, 2017, based on positive results from deutetrabenazine clinical trials, the Phase III randomized, placebo-controlled study called First-HD Total Maximal Chorea Scores were averaged over the maintenance period (week 9 to week 12)